Imaging software developer Median Technologies has reported a 51% revenue increase for fiscal year 2020.
For the year (end-December 31), Median's revenues jumped to 13.5 million euros ($16.1 million) compared with revenues of 9 million euros ($10.7 million) in 2019. The company attributed the increase in part to its iCRO business unit, which provides services for oncology clinical trials.
As for its first quarter (end-March 31), Median's revenue increased 86%, from 2.8 million euros ($3.3 million U.S.) in the first quarter of 2020 to 5.2 million euros ($6.2 million U.S.) for the same period this year.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
